Proactiveinvestors recommends
Additional Information
Market: LON
Sector: Pharmaceuticals
EPIC: AMP
Amphion Innovations
www.amphionplc.com

Amphion builds shareholder value in high growth companies in the medical and technology sectors, by using a focused, hands-on company building approach, based on decades of experience in both the US and UK.

Amphion has a significant shareholding in 8 Partner Companies developing proven technologies targeting substantial commercial marketplaces, each in excess of $1 billion. Each Partner Company is chosen with the goal of achieving an exit valuation in excess of $100 million.

Full Amphion Innovations profile here
Pdf

Amphion Innovations investee Kromek’s CEO Arnab Basu named ‘Ernst & Young Entrepreneur Of The Year’

9th Oct 2009, 7:07 am
Amphion Innovations investee Kromek’s CEO Arnab Basu named ‘Ernst & Young Entrepreneur Of The Year’

Amphion Innovations PLC (AIM: AMP) said Arnab Basu,  the chief executive officer of its investee company Kromek Ltd, was named "The Ernst & Young Entrepreneur Of The Year” at an award ceremony last night.

To reach the national final, Basu was named as one of 14 winners from the North and Midlands. On the night, he won over two other candidates shortlisted for the award.

Amphion said Basu was described by the judges as "a great leader and manager with great vision" and a "supreme innovator who has developed ground-breaking, unique technology for an existing market set to boom”.

Kromek is a venture backed high technology company, which was spun-out in April 2003 as Durham Scientific Crystals from the Physics Department of the University of Durham. Rebranded as Kromek in May 2008, it is pioneering digital colour imaging for x-rays, it specialises in making semiconductor materials within the Cadmium Telluride family.

These materials have significant applications as detectors of x-rays and gamma-rays, notably in medical imaging, security screening, industrial inspection, and space exploration, allowing for very precise identification of materials. Cadmium Zinc Telluride is also the material of choice as a substrate for the fabrication of infrared detectors in both civilian and military markets. In addition to its range of semiconductor materials, detector packages, and non imaging detection systems.

 Kromek also supplies x-ray imaging packages with multi-view capabilities, providing real 3D x-ray imaging without specialist viewing equipment.
 
The market place opportunities for Kromek’s imaging and non-imaging technology are in the security, industrial inspection, medical, and defence sectors. These are high growth rate markets and provide exciting prospects for Kromek’s capability, Amphion said.

Kromek drew extensive media coverage last month following reports that the EU is testing its liquid detection scanners at a number of airports, with the group being mentioned in most mainstream UK media sources, including the Guardian, Independent and the BBC.

Kromek’s profile was further boosted after it picked up an award at the Global Security Challenge in Brussels. Kromek was announced as the winner of the western European section of the competition in Brussels among the companies with revenues between £1 and £10 million.

The company drew praise for “breaking boundaries and solving problems which others have tried to solve over many years” by developing an x-ray technology which can distinguish dangerous chemicals from other similar looking liquids. Failed bombings of transatlantic flights with liquid explosives by al-Quaeda inspired terrorists back in 2006 led to the introduction of enhanced security measures which are estimated to have cost British airlines and airports £100 million.

Amphion holds a 19.99 percent stake in Kromek. Amphions’ other investments include Firestar Software (15.3%), Axcess International (8.5%), Motif Biosciences (38.5%), MSA Holdings B.S.C. (50%), M2M Imaging Corp (24.4%), Myconostica (22%), Private Markets (25%), WellGen (14.6%), and DataTern (100%).

No investment advice

The Company is a publisher and is not registered with or authorised by the Financial Services Authority (FSA). You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.